论文部分内容阅读
目的：研究蛋白激酶Ｃα（ＰＫＣα）在人肺癌ＬＴＥＰａ２细胞对一些临床抗肿瘤药物敏感性中的作用．方法：通过基因转染，免疫印迹等方法建立表达反义ＰＫＣα的人肺癌细胞模型，Ｎｏｒｔｈｅｒｎ印迹检测多药抗性基因的表达，分析了几种抗癌药物对培养细胞的ＩＣ５０．结果：表达反义ＰＫＣαＲＮＡ降低胞内ＰＫＣα水平时可抑制肺癌细胞中多药抗性基因的表达，增强肺癌细胞对抗肿瘤药物（三尖杉酯碱、卡铂、博来霉素、长春新碱、阿霉素）的敏感性．结论：ＰＫＣα在人肺癌细胞多药抗性基因的表达以及药物敏感性中具有重要调节作用
Objective: To investigate the role of protein kinase Cα (PKCα) in the sensitivity of LTEPa2 cells to some clinical antitumor drugs in human lung cancer. Methods: Human lung cancer cell model expressing antisense PKCα was established by gene transfection and western blotting. The expression of multidrug resistance gene was detected by Northern blotting. The IC50 of several anticancer drugs on cultured cells was analyzed. Results: The expression of antisense PKCαRNA could inhibit the expression of multidrug resistance gene in lung cancer cells when it decreased the intracellular PKCα level, and enhance the anti-tumor activity of anticancer drugs (harringtonine, carboplatin, bleomycin, vincristine, Doxorubicin) sensitivity. Conclusion: PKCα plays an important regulatory role in the expression of multidrug resistance genes and drug sensitivity in human lung cancer cells